|Security||CMD / Cantel Medical Corp|
|CEO||Krakauer Andrew A|
|Industry||Surgical and Medical Instruments and Apparatus|
|Common Stock Shares Outstanding||41,709,335 shares (as of 2018-04-30)|
CMN / Cantel Medical Corp.|
Institutional Stock Ownership and Shareholders
Cantel Medical Corp (NYSE:CMD) has 0 institutional investors and shareholders that have
filed 13D/G or 13F forms with the Securities Exchange Commission (SEC).
Largest shareholders include
Cantel Medical Corp (NYSE:CMD) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.
6h - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
Related News Stories
Micron (MU - Free Report) came out with quarterly earnings of $3.53 per share, beating the Zacks Consensus Estimate of $3.32 per share. This compares to earnings of $2.02 per share a year ago. These figures are adjusted for non-recurring items. (1-0)
United Natural Foods (UNFI - Free Report) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.85 per share. This compares to earnings of $0.72 per share a year ago. These figures are adjusted for non-recurring items. (5-0)
Wall Street expects a year-over-year increase in earnings on higher revenues when Cantel Medical (CMD - Free Report) reports results for the quarter ended July 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
It has been six months since I presented four hedged portfolios and 10 top names in week 42 of my Marketplace service (March 15). Here's how everything did. (10-0)
It's been six months since I presented 4 hedged portfolios and 10 top names in week 38 of my Marketplace service (February 15th). Here's how everything did. (11-0)
When MOTS' 180 lockup period expires on August 13th, pre-IPO shareholders and company insiders will be able to sell more than 10 million currently-restricted shares. (3-2)
Wall Street doesn’t always get it right, but analysts’ track record is better than some skeptics suggest. And when the Street as a whole is arguing for big upside, investors should at least consider what those analysts have to say. (982-14)
Cantel Medical (CMD) is a high quality growth company that is likely to significantly grow its earnings over the next 5 years. The company supplies a diverse set of very stable and growing medical end-markets. The company has a strong track record of generating organic growth but has also demonstrated an ability to grow inorganically through bolt-on acquisitions. (20-0)
This week's Editor's Notes covers a few ideas on the long side that tend to appeal to value investors - the insurance company, the holding company, international growth. (53-0)
Greetings and welcome to the Cantel Medical Corp Third Quarter 2018 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Milicent Brooks, Head of Corporate Communications at Cantel Medical. Thank you, Ms. Brooks. You may begin. (8-1)
as of ET